[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-or-metastatic-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-or-metastatic-ovarian-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100642622","phase-2-a-study-of-dat-2645-in-patients-with-brca12-mutations-or-hrd-positive-ovarian-cancer-100642622",false,"NCT07652073","A Study of DAT-2645 in Patients With BRCA1\u002F2 Mutations or HRD-Positive Ovarian Cancer","A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of DAT-2645 in Patients With BRCA1\u002F2 Deleterious Mutations or HRD-Positive Advanced\u002FMetastatic Ovarian Cancer","Inclusion Criteria:\n\n* sign a written informed consent form\n* At least 18 years of age (inclusive)\n* Epithelial ovarian cancer confirmed by histopathology or cytopathology\n* BRCA1\u002F2 mutation or HRD-positive status\n* Patients who have failed standard treatment or are unable to tolerate standard treatment\n* Patients must have received no more than five prior treatment lines\n* At least one measurable lesion\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Bone marrow reserve and organ function must meet the requirements\n* Negative result on a blood pregnancy test for a woman of childbearing age\n\nExclusion Criteria:\n\n* Received small-molecule chemotherapy or targeted therapy within 2 weeks or 5 half-lives prior to the first dose\n* Received treatment with an anticancer biological therapy within 4 weeks prior to the first dose\n* Underwent major surgery within 4 weeks prior to the first dose\n* Has previously received treatment with a PARG inhibitor\n* Inadequate response to previous PARP inhibitor maintenance therapy\n* With central nervous system metastases\n* Patients with clinically significant cardiovascular or cerebrovascular diseases\n* Uncontrolled active infections requiring intravenous antibiotics or hospitalization\n* Adverse reactions from prior anticancer therapy have not yet resolved to a grade ≤1","FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645",[26],"Advanced or Metastatic Ovarian Cancer","NOT_YET_RECRUITING","2026-06-21",{"date":30,"type":31},"2026-06-25","ACTUAL",{"date":33,"type":20},"2026-06-15",{"date":35,"type":20},"2028-03-30",{"name":37,"class":38},"Danatlas Pharmaceuticals Co., Ltd","INDUSTRY",2]